Morningstar CIO: The shining investment opportunities beyond technology
There are still plenty of undervalued equities to take advantage of despite soaring tech shares, writes Mike Coop
There are still plenty of undervalued equities to take advantage of despite soaring tech shares, writes Mike Coop
|
|
Obesity drugs are at a revolutionary moment comparable to the launch of the iPhone, writes Ben Kluftinger
|
|
Exciting developments are underway in the healthcare world, and these three companies are leading that change
|
|
Antidiabetic drugs such as Ozempic have markets excited about healthcare, but AllianceBernstein’s Vinay Thapar calls for caution amongst the hype
|
|
Catherine Tennyson joins from Point 72 Asset Management
|
|
Demand for GLP-1 medications is skyrocketing
|
|
The sector looks set to thrive again this year after a strong 2023, but there is more to tech than just AI
|
|
The global equity team discusses AI, the energy transition, global travel and healthcare efficiency
|
|
European equity funds bruised by global manufacturing slowdown
|
|
The new offering aims to outperform the MSCI World Health Care Index
|
|
Stonehage Fleming’s Gerrit Smit discusses the fourth industrial revolution, the reopening of China and currency movements
|
|
Polar Capital’s Deane Donnigan tells Portfolio Adviser how she moved from clinical pharmacist to fund manager
|
|